ALK and osteosarcoma: Due to the identification of an alternative transcript (ATI) on ALK, the patient with osteosarcoma underwent a targeted therapy with the ALK-inhibitor crizotinib, which would likely not have been identified in our in-house panel testing (Schoch et al. 2020).